USANA Health Sciences (NYSE:USNA) PT Lowered to $35.00 at DA Davidson

USANA Health Sciences (NYSE:USNA - Free Report) had its target price reduced by DA Davidson from $38.00 to $35.00 in a research report released on Wednesday morning, Benzinga reports. DA Davidson currently has a neutral rating on the stock.

Separately, StockNews.com cut shares of USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, July 24th.

USANA Health Sciences Trading Up 6.1 %

NYSE USNA traded up $2.10 during trading hours on Wednesday, hitting $36.58. 158,106 shares of the company's stock were exchanged, compared to its average volume of 80,305. The firm has a market cap of $696.89 million, a price-to-earnings ratio of 11.40, a PEG ratio of 1.20 and a beta of 0.89. The stock has a 50-day simple moving average of $37.98 and a 200 day simple moving average of $42.55. USANA Health Sciences has a 1-year low of $34.15 and a 1-year high of $55.45.

USANA Health Sciences (NYSE:USNA - Get Free Report) last announced its quarterly earnings data on Tuesday, October 22nd. The company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.49 by $0.07. The company had revenue of $200.22 million during the quarter, compared to the consensus estimate of $208.45 million. USANA Health Sciences had a net margin of 6.29% and a return on equity of 11.13%. During the same quarter last year, the firm posted $0.59 EPS. On average, sell-side analysts anticipate that USANA Health Sciences will post 2.5 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Paul A. Jones sold 6,266 shares of the firm's stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $38.38, for a total value of $240,489.08. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, insider Paul A. Jones sold 6,266 shares of the stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $38.38, for a total value of $240,489.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Gilbert A. Fuller sold 674 shares of the business's stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $39.69, for a total value of $26,751.06. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 7,940 shares of company stock worth $311,670. Insiders own 0.33% of the company's stock.

Institutional Investors Weigh In On USANA Health Sciences

Several large investors have recently modified their holdings of the stock. American Century Companies Inc. raised its stake in shares of USANA Health Sciences by 12.3% in the second quarter. American Century Companies Inc. now owns 159,782 shares of the company's stock valued at $7,229,000 after buying an additional 17,460 shares during the period. Pzena Investment Management LLC lifted its holdings in USANA Health Sciences by 24.4% during the second quarter. Pzena Investment Management LLC now owns 976,633 shares of the company's stock valued at $44,183,000 after purchasing an additional 191,289 shares during the last quarter. Deerfield Management Company L.P. Series C lifted its holdings in USANA Health Sciences by 297.0% during the second quarter. Deerfield Management Company L.P. Series C now owns 29,742 shares of the company's stock valued at $1,346,000 after purchasing an additional 22,251 shares during the last quarter. Panagora Asset Management Inc. boosted its position in USANA Health Sciences by 143.1% during the second quarter. Panagora Asset Management Inc. now owns 28,881 shares of the company's stock worth $1,307,000 after purchasing an additional 16,999 shares during the period. Finally, Bank of New York Mellon Corp increased its stake in shares of USANA Health Sciences by 5.6% in the second quarter. Bank of New York Mellon Corp now owns 97,375 shares of the company's stock worth $4,405,000 after purchasing an additional 5,205 shares in the last quarter. Hedge funds and other institutional investors own 54.25% of the company's stock.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.